Metabolic syndrome(MetS)is a cluster of metabolic disorders with diverse clinical manifestations.Jingui Yaolue,or Synopsis of the Golden Chamber,discusses over 40 different diseases in total.This study reveals that some of these diseases,including tanyin(phlegm-dampness),xulao(consumptive disease),and xiaoke(wasting and thirst),exhibit clinical manifestations similar to those of MetS.Furthermore,there are also correspondences between these diseases and MetS in terms of the etiology and pathogenesis.For example,the pathogenesis involves multiple organs,but is centered on the spleen;the disease arises from deficiency and ultimately leads to a dual deficiency of yin and yang;the syndrome patterns are complex and predominantly characterized by phlegm-turbidity.This article summarizes targeted treatment approaches for MetS mentioned in Synopsis of the Golden Chamber,including focusing on the spleen in the treatment of diseases involving multiple organs,supporting the vital energy while dealing with excess syndrome,balancing yin and yang in a state of dual deficiency of both yin and yang,and treating phlegm and blood stasis simultaneously due to the close connection between body fluids and blood.Integrating these treatment principles into current traditional Chinese medicine treatment plans for MetS may help optimize traditional Chinese medicine treatment protocols for MetS and improve clinical outcomes.

Objective:To prepare aldolylated hyaluronic acid-modified antimicrobial carbon dots (AHA-CDs) eye drops and evaluate its antibacterial activity against Staphylococcus aureus in vitro and in vivo. Methods:AHA-CDs eye drops were synthesized by modifying small particle size positively charged carbon dots and introducing aldehyde-based hyaluronic acid.The AHA-CDs were characterized by transmission electron microscopy, Fourier transform infrared spectroscopy, and X-ray photoelectron spectroscopy.The antibacterial activity of AHA-CDs against Staphylococcus aureus was evaluated using the microdilution method, plate counting, and live-dead bacteria fluorescence staining in vitro.The mouse bacterial keratitis model was established by removing the corneal epithelium after ring drilling and inoculating Staphylococcus aureus.Eighteen conventional female C57BL/6 mice aged 6-8 weeks were selected and divided into a blank control group, an AHA-CDs-treated group and a tobramycin-treated group of 6 mice each using random number table method, and the mice were treated with phosphate buffer saline, 80 μg/ml AHA-CDs, and 80 μg/ml tobramycin eye drops three times daily for 5 consecutive days accordingly to assess antibacterial activity against Staphylococcus aureus in vivo.Another 12 mice were divided into an AHA-CDs group and a normal control group using the random number table method, with 6 mice in each group, which were treated with 80 μg/ml AHA-CDs and phosphate buffer saline for 7 days.The mice were then sacrificed.Their eyeballs were removed and stained with hematoxylin-eosin to observe and compare the morphology and integrity of the eyeballs between the two groups to evaluate the treatment's biosafety.The use and care of the animals complied with the principles of the ARRIVE guidelines.The study protocol was approved by the Ethics Committee of the Experimental Animal Care of Henan Eye Hospital (No.HNEECA-2022-17). Results:The successful preparation of AHA-CDs was demonstrated by transmission electron microscopy, Fourier transform infrared spectroscopy, and X-ray photoelectron spectroscopy. In vitro studies showed that the minimum inhibitory concentration of AHA-CDs against Staphylococcus aureus was approximately 8 μg/ml, which effectively inhibited bacterial growth at a lower concentration.Plate counting results showed that only 20% of the bacteria survived after 10 minutes of treatment with AHA-CDs.Fluorescence staining of live/dead bacteria showed obvious red fluorescence signals after 4 hours of treatment with AHA-CDs and SP-CDs. In vivo studies showed that, after 5 days of treatment with AHA-CDs eye drops, the corneas of mice with bacterial keratitis were obviously transparent, and the corneal epithelium was basically repaired.In contrast, the tobramycin-treated group exhibited incomplete epithelial repair and mild corneal edema. In vivo safety evaluation revealed that the eye tissue morphology remained intact and no structural abnormalities were observed after AHA-CDs treatment. Conclusions:AHA-CDs eye drops have superior antibacterial effects in vivo and in vitro, and inactivate bacteria rapidly and effectively.

Neuropeptides, as a class of small molecule active substances with neuroregulatory and immunomodulatory functions, play a key role in the physiological and pathological processes of the cornea.Neuropeptides are synthesized, stored, and secreted by the trigeminal neurons that innervate the cornea, and communicate with immune cells, epithelial cells, and stromal cells through G protein-coupled receptors, forming a complex signaling network that maintains ocular surface homeostasis.Under normal circumstances, the release of neuropeptides promotes corneal repair and prevents pathogen invasion.However, abnormal neuropeptide synthesis or receptor dysfunction can lead to an imbalance in ocular surface homeostasis, triggering various eye diseases.This article systematically reviews the research progress of neuropeptides in corneal diseases, focusing on the mechanism of action and therapeutic potential of key neuropeptides such as calcitonin gene-related peptide, substance P, and neuropeptide Y in corneal injury repair, inflammation regulation, nerve regeneration, and pain management.At the same time, this articles discusses the development of new drug delivery strategies, the research progress of neuropeptide modulators, as well as the current challenges and future development directions to provide theoretical basis and new ideas for the clinical treatment of corneal diseases.

Objective:To prepare aldolylated hyaluronic acid-modified antimicrobial carbon dots (AHA-CDs) eye drops and evaluate its antibacterial activity against Staphylococcus aureus in vitro and in vivo. Methods:AHA-CDs eye drops were synthesized by modifying small particle size positively charged carbon dots and introducing aldehyde-based hyaluronic acid.The AHA-CDs were characterized by transmission electron microscopy, Fourier transform infrared spectroscopy, and X-ray photoelectron spectroscopy.The antibacterial activity of AHA-CDs against Staphylococcus aureus was evaluated using the microdilution method, plate counting, and live-dead bacteria fluorescence staining in vitro.The mouse bacterial keratitis model was established by removing the corneal epithelium after ring drilling and inoculating Staphylococcus aureus.Eighteen conventional female C57BL/6 mice aged 6-8 weeks were selected and divided into a blank control group, an AHA-CDs-treated group and a tobramycin-treated group of 6 mice each using random number table method, and the mice were treated with phosphate buffer saline, 80 μg/ml AHA-CDs, and 80 μg/ml tobramycin eye drops three times daily for 5 consecutive days accordingly to assess antibacterial activity against Staphylococcus aureus in vivo.Another 12 mice were divided into an AHA-CDs group and a normal control group using the random number table method, with 6 mice in each group, which were treated with 80 μg/ml AHA-CDs and phosphate buffer saline for 7 days.The mice were then sacrificed.Their eyeballs were removed and stained with hematoxylin-eosin to observe and compare the morphology and integrity of the eyeballs between the two groups to evaluate the treatment's biosafety.The use and care of the animals complied with the principles of the ARRIVE guidelines.The study protocol was approved by the Ethics Committee of the Experimental Animal Care of Henan Eye Hospital (No.HNEECA-2022-17). Results:The successful preparation of AHA-CDs was demonstrated by transmission electron microscopy, Fourier transform infrared spectroscopy, and X-ray photoelectron spectroscopy. In vitro studies showed that the minimum inhibitory concentration of AHA-CDs against Staphylococcus aureus was approximately 8 μg/ml, which effectively inhibited bacterial growth at a lower concentration.Plate counting results showed that only 20% of the bacteria survived after 10 minutes of treatment with AHA-CDs.Fluorescence staining of live/dead bacteria showed obvious red fluorescence signals after 4 hours of treatment with AHA-CDs and SP-CDs. In vivo studies showed that, after 5 days of treatment with AHA-CDs eye drops, the corneas of mice with bacterial keratitis were obviously transparent, and the corneal epithelium was basically repaired.In contrast, the tobramycin-treated group exhibited incomplete epithelial repair and mild corneal edema. In vivo safety evaluation revealed that the eye tissue morphology remained intact and no structural abnormalities were observed after AHA-CDs treatment. Conclusions:AHA-CDs eye drops have superior antibacterial effects in vivo and in vitro, and inactivate bacteria rapidly and effectively.

Neuropeptides, as a class of small molecule active substances with neuroregulatory and immunomodulatory functions, play a key role in the physiological and pathological processes of the cornea.Neuropeptides are synthesized, stored, and secreted by the trigeminal neurons that innervate the cornea, and communicate with immune cells, epithelial cells, and stromal cells through G protein-coupled receptors, forming a complex signaling network that maintains ocular surface homeostasis.Under normal circumstances, the release of neuropeptides promotes corneal repair and prevents pathogen invasion.However, abnormal neuropeptide synthesis or receptor dysfunction can lead to an imbalance in ocular surface homeostasis, triggering various eye diseases.This article systematically reviews the research progress of neuropeptides in corneal diseases, focusing on the mechanism of action and therapeutic potential of key neuropeptides such as calcitonin gene-related peptide, substance P, and neuropeptide Y in corneal injury repair, inflammation regulation, nerve regeneration, and pain management.At the same time, this articles discusses the development of new drug delivery strategies, the research progress of neuropeptide modulators, as well as the current challenges and future development directions to provide theoretical basis and new ideas for the clinical treatment of corneal diseases.

Objective To investigate the relationship between serum glutamate levels and severity of retinopathy of prematurity (ROP) in children and its impact on the prognosis.Methods A total of 92 children with ROP who were screened and treated at Henan Provincial Eye Hospital from June 2017 to June 2018 and 50 healthy preterm infants screened at Henan Provincial Eye Hospital were selected for clinical control study.Ninety-two children with ROP were divided into the mild ROP group and the severe ROP group according to the stage of lesions,and they were divided into the progressive group and the spontaneous regression group according to whether the disease was progressive.The severity of ROP and prognosis were analyzed by measuring serum glutamate levels in 1 week and 6 weeks after birth.Results The serum glutamate concentration in the severe ROP group was the highest in the first week after birth [(122.08 ± 14.55) mmol/L] and in the 6th week after birth [(107.13 ± 13.20) mmol/L],followed by the mild ROP group[(98.60 ± 14.48) mmol/L,(85.41 ± 14.49) mmol/L] separately,and the lowest in the control group[(68.52 ±7.69) mmol/L,(54.97 ± 6.31) mmol/L] separately,and there were significant differences among the 3 groups (all P ＜ 0.05).Pearson correlation analysis showed that serum glutamate concentration was positively correlated with the severity of ROP at 1 week and 6 weeks after birth (r =0.869,0.875,all P ＜ O.05).The levels of serum glutamate at the first week after birth and at the 6th week after birth in the progressive group [(107.18 ± 17.62) mmol/L,(92.94 ±16.21) mmol/L] were significantly higher than those in the spontaneous regression group[(131.53 ± 10.22) mmol/L,(118.82 ± 8.18) mmol/L],and there were significant differences between the 2 groups (all P ＜0.05).The area under the curve(AUC) values of serum glutamate concentration at 1 week after birth and 6 weeks after birth were 0.855and 0.936,respectively,according to the receiver operating characteristic(ROC) curve,while the optimal critical valuesof serum glutamate concentration at 1 week and 6 weeks after birth were 117.83 mmol/L (sensitivity was 0.909,specificity was 0.728) and 106.69 ng/L (sensitivity was 1.000,specificity was 0.790),respectively.Conclusions The serum glutamate concentration was positively correlated with the severity of ROP infants in 1 week and 6 weeks after birth.The optimal threshold of serum glutamate concentration in 1 week and 6 weeks after birth was more sensitive and specific in predicting the progression of retinopathy,and had higher value in evaluating the prognosis of the infants.

Objective: To investigate the relationship between serum glutamate levels and severity of retinopathy of prematurity (ROP) in children and its impact on the prognosis. Methods: A total of 92 children with ROP who were screened and treated at Henan Provincial Eye Hospital from June 2017 to June 2018 and 50 healthy preterm infants screened at Henan Provincial Eye Hospital were selected for clinical control study.Ninety-two children with ROP were divided into the mild ROP group and the severe ROP group according to the stage of lesions, and they were divided into the progressive group and the spontaneous regression group according to whether the disease was progressive.The severity of ROP and prognosis were analyzed by measuring serum glutamate levels in 1 week and 6 weeks after birth. Results: The serum glutamate concentration in the severe ROP group was the highest in the first week after birth[(122.08±14.55) mmol/L] and in the 6^th week after birth [(107.13±13.20) mmol/L], followed by the mild ROP group[(98.60±14.48) mmol/L, (85.41±14.49) mmol/L] separately, and the lowest in the control group[(68.52±7.69) mmol/L, (54.97±6.31) mmol/L] separately, and there were significant differences among the 3 groups (all P<0.05). Pearson correlation analysis showed that serum glutamate concentration was positively correlated with the severity of ROP at 1 week and 6 weeks after birth (r=0.869, 0.875, all P<0.05). The levels of serum glutamate at the first week after birth and at the 6^th week after birth in the progressive group [(107.18±17.62) mmol/L, (92.94±16.21) mmol/L]were significantly higher than those in the spontaneous regression group[(131.53±10.22) mmol/L, (118.82±8.18) mmol/L], and there were significant differences between the 2 groups (all P<0.05). The area under the curve(AUC) values of serum glutamate concentration at 1 week after birth and 6 weeks after birth were 0.855 and 0.936, respectively, according to the receiver operating characteristic(ROC) curve, while the optimal critical values of serum glutamate concentration at 1 week and 6 weeks after birth were 117.83 mmol/L (sensitivity was 0.909, specificity was 0.728) and 106.69 ng/L (sensitivity was 1.000, specificity was 0.790), respectively. Conclusions The serum glutamate concentration was positively correlated with the severity of ROP infants in 1 week and 6 weeks after birth.The optimal threshold of serum glutamate concentration in 1 week and 6 weeks after birth was more sensitive and specific in predicting the progression of retinopathy, and had higher value in evaluating the prognosis of the infants.

Objective: To explore the genotype-phenotype correlation among 3 pedigrees affected with congenital aniridia. Methods: Clinical data and genomic DNA were collected and genetic variations were screened by whole-exome sequencing, with an emphasis on PAX6-related genes.Suspected variations were verified by Sanger sequencing and quantitative polymerase chain reaction (PCR). Written informed consent was obtained from the parents of each propositus prior to entering study cohort.This study protocol was approved by Ethic Committee of Henan Eye Hospital (No.HNEECKY-2017(6)). Results: Genetic analysis identified that a nonsense c. 949 C>T variation and an c. 141+ 1 G>T splicing variation of the PAX6 gene in two of the probands, while the remainder has carried a duplication in 11 p13 (chr11: 31531331-31827959) encompassing the PAX6 and ELP4 genes.Phenotype analysis showed that the probands carrying the nonsense and splicing variations had classical features including complete aniridia, macular hypoplasia, microcornea and nystagmus; the proband carrying the 11p13 duplication had microphthalmos, microcornea, macular dysplasia, iris dysgenesis, and nystagmus. Conclusions The 11p13 duplication involving the PAX6 gene may have caused over-expression of PAX6 gene, resulting in severe eye abnormalities including microphthalmos and microcornea, macular dysplasia and nystagmus.The relatively mild iris dysgenesis has distinguishing it from classical aniridia due to PAX6 haploinsufficiency.

Objective To investigate the corneal permeability of cyclosprin A (CsA) loaded on polymeric vector after topical application.Methods The grafted copolymer chitosan-graft-cyclodextrin (CS-g-CD) was synthesized,and the physicochemical structures of the polymer were investigated using nuclear magnetic resonance spectroscopy (NMR) and fourier transform infrared spectroscopy (FT-IR).A novel CsA eye drop was prepared using the grafted copolymer as carrier material.The physicochemical properties of eye drop,including drug-loading content,osmotic pressure and viscosity were investigated by high performance liquid chromatography-mass spectrometry (HPLC-MS),osmotic pressure gauge and viscometer,respectively.New Zealand albino rabbits were randomly divided into intact cornea CsA group,epithelium debrided CsA group and epithelium debrided control group.The corneal epithelia of the left eyes was debrided in the cornea epithelium debrided group.Cornea irritation test was performed on New Zealand albino rabbits.The aqueous humor was taken and the corneas were collected at 0.5 hour and 1 hour after instilled.The concentration of CsA was measured by HPLC-MS.Cy5 labeled vector loaded with Coumarin 6 served as model copolymers system,the penetration capabilities of the double fluorescent labeling copolymers system were monitored in vivo using two-photon scanning fluorescence microscopy on murine corneas after topical application.The use and care of the animals complied with Regulations for the Administration of Affair Concerning Experimental Animals by State Science and Technology Commission.Results The polymer of CS-g-CD was successfully synthesized and confirmed using NMR and FT-IR.The drug loading of CsA in eye drop solution was 0.06 ％;the osmotic pressure was 305 mOsmol/kg and the viscosity was 36.5 cP.The CsA drug delivery system had a reversible temperature-sensitive drug release behavior and had no obvious irritation on the eyes of New Zealand rabbits.One hour after treatment,the concentration of CsA in the cornea and aqueous humor of epithelium debrided CsA group was (5.88 ± 1.46) μg/g and (149.19 ± 3.93) ng/ml,respectively,which was significantly higher than (3.98 ±0.95) μg/g and (30.25± 11.43) ng/ml in epithelium debrided control group (both at P＜0.05);the concentration of CsA in the aqueous humor of intact cornea CsA group was (7.23 ± 1.31)ng/ml,which was significantly lower than that in epithelium debrided CsA group (P＜0.05).Polymer vectors were mainly retained in the corneal epithelium,and coumarin 6 gradually diffused into the deep corneal stroma with time.Conclusions The grafted copolymer can load CsA,and the eye drop can effectively overcome the corneal barrier and increase the corneal permeability of CsA.

Objective To compare the morphological and functional outcomes of different degrees of ocular burns patients receiving amniotic membrane transplantation (AMT) at different time points after ocular burn.Methods A retrospective analysis was performed.Ninety-two eyes of 76 acute ocular chemical burn patients were enrolled from January 2012 to December 2016 in Henan Eye Hospital.The ocular chemical burns were classified by Dua classifications.According to the operation time of AMT,the patients were divided into within 1 day after injury group,2-6 days after injury group and more than 6 days after injury group.The best corrected visual acuity and limbal stem cell deficiency score were recorded during the at least one year of follow up.The risk factors affecting limbal stem cell deficiency and visual outcome were analyzed.Results Of all the burned eyes,29 eyes (31.5 ％) were result from acid burn,41 eyes(44.6％) were result from alkaline burns and 22 eyes (23.9％) were result from thermal burn.The average burn severity scores of patients with limbal stem cell deficiency score of 0,1 and 2 was 1.86±0.54,3.60±0.94 and 5.35 ± 0.63,respectively,and the overall difference was statistically significant (F =65.532,P ＜0.01).In mild to moderate ocular surface burn patients,the limbal stem cell deficiency score in more than 6 days after injury group was significantly higher than that in within 1 day after injury group and 2-6 days after injury group (Z=-2.21,P=0.03;Z=-2.33,P=0.02).In severe ocular surface burn patients,there was no significant difference in limbal stem cell deficiency score between the groups (P=0.26).At the last follow-up,the average visual acuity of all eyes was 3.19 ± 1.47.COX regression analysis showed that burn grade and operation timing were the main risk factors for visual prognosis (OR =4.925,1.368;both at P＜0.01).Prognostic visual acuity was linearly correlated with the timing of amniotic membrane occlusion and degree of burn (R2 =0.078,0.685;both at P＜0.01),but for the Ⅴ grade and Ⅵ grade eyes,amniotic membrane timing couldn't improve the score of limbal stem cell deficiency.Conclusions Dua classifications is of great significance in evaluating prognosis of ocular burn patients.AMT is an effective adjunctive treatment in the management of acute ocular chemical burns to support epithelial healing and restore ocular surface integrity with potential to improve vision.AMT can't prevent limbal stem cell deficiency or restore vision in eyes with severe burns.